Tivdak success could make life even harder for Iovance
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Olema takes its antagonist/degrader concept into phase 3
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
Point looks to make a year-end Splash
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Roche stakes its KRAS claim
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
Another twist in the TIGIT saga
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
Exelixis claims a label-expanding Cabo success at last
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
